Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT02583061
Recruiting Observational

Toronto Gestational Glucose Tolerance Cohort

NCT02583061 · tracked via the Priya Life Science Canada tracker
Sponsor
Mount Sinai Hospital, Canada
Phase
Observational
Started
2003-09
Last updated
2025-05-09

Condition(s) studied

Type 2 Diabetes, Gestational Diabetes, Pre-diabetes

Investigational drug(s) / intervention(s)

There is no intervention. An exposure of interest is glucose tolerance status in pregnancy

Study summary

In this prospective observational cohort study, women representing the full spectrum of gestational glucose tolerance status are undergoing longitudinal cardiometabolic characterization at regular intervals in the years after the index pregnancy.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Pregnant women Exclusion Criteria: * Pre-existing diabetes before the index pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Mount Sinai Hospital Toronto Ontario Recruiting

More Mount Sinai Hospital, Canada trials in Canada

Diet Intervention Treatment for Active Ulcerative Colitis Recruiting
Antibiotics for Delirium in Older Adults With No Clear Urinary Tract Infection Recruiting
The CanDo (Canadian Donor Milk) Trial Active, not recruiting
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants Recruiting
Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02583061 on ClinicalTrials.gov ↗ ← All trials in Canada